Acusphere Appoints Dr. William Ramage as Chief Development Officer
2013年11月6日 - 10:00PM
ビジネスワイヤ（英語）
Acusphere, Inc. (ACUSD.PK) today announced that William I.
Ramage, D. Phil., has been appointed Chief Development Officer of
the Company. Acusphere is focused on the development of Imagify™
(Perflubutane Polymer Microspheres for Injectable Suspension),
which if approved for sale, will be a novel cardiovascular drug for
the detection of coronary artery disease (CAD), the leading cause
of death in the United States and Europe.
Mark Leuchtenberger, Acusphere’s President and CEO, said,
“Bill’s three-plus decades of experience in the imaging industry,
his understanding of current market dynamics, his personal
relationships with key opinion leaders and his strong working
relationship with the Acusphere team make him the ideal person to
step into this dedicated role as Chief Development Officer.”
“I have had the pleasure of working on the development of
Imagify for the last 14 years as a consultant and I am honored to
join the Acusphere management team,” said Dr. Ramage.
Dr. Ramage brings with him over 30 years of imaging experience,
25 of which have been dedicated to cardiovascular imaging. He
served as an Executive Consultant at Acusphere from March 2000 to
October 2013 where he was responsible for key clinical and
regulatory activities and as an Independent Business Development
and Strategic Marketing Consultant from August 1999 until March
2000. Dr. Ramage has also served as a consultant to numerous
companies, primarily in the cardiovascular imaging industry. Prior
to Acusphere, Dr. Ramage was Vice President of Business Development
and Customer Services at DuPont-Merck (now Lantheus) and had major
business responsibility for the leading nuclear perfusion agent,
Cardiolite®, and in-licensed the ultrasound contrast agent,
Definity®. Dr. Ramage also served previously as Vice President,
Business Development and Marketing at Molecular BioSystems, where
he oversaw the approval and launch of Optison® in the U.S. and
Europe. Dr. Ramage holds a B.Sc. from the University of Glasgow and
a D.Phil. from Oxford University.
About Acusphere, Inc.
Acusphere, Inc. (ACUSD.PK) is a specialty pharmaceutical company
focused on the development and regulatory approval of our lead
product candidate, Imagify™ (Perflubutane Polymer Microspheres for
Injectable Suspension). Imagify is a cardiovascular drug for the
detection of coronary artery disease, the leading cause of death in
the United States and Europe. Imagify was created using proprietary
technology that enables Acusphere to control the porosity and size
of nanoparticles and microparticles, which were customized to
control the delivery of gas needed for ultrasound myocardial
perfusion assessment. For more information about Acusphere visit
the Company's web site (www.acusphere.com).
MacDougall Biomedical CommunicationsKari Watson,
781-235-3060kwatson@macbiocom.comorBianca Nery,
781-235-3060bnery@macbiocom.com
Acusphere (CE) (USOTC:ACUS)
過去 株価チャート
から 11 2024 まで 12 2024
Acusphere (CE) (USOTC:ACUS)
過去 株価チャート
から 12 2023 まで 12 2024
